About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The research group is focused on finding new molecular therapeutic targets and biomarkers based on knowledge of the biology of paediatric tumours, leukemias and hematologic diseases. The experience of the group in recent years has permitted the identification of new molecular targets that are very close to the clinical phase. In this stage, we have consolidated collaborations with the biotechnological industry in order to develop small molecules able to inhibit pro-oncogenic processes such as invasion or proliferation, with the aim of providing patients with innovative and more specific biological evidence-based therapies.
Another line of research is based on the study of liquid biopsy to develop a system based on NGS to monitor the probability of relapses.
Furthermore, we have implemented a personalized medicine program to guide the management of patients based on the molecular alterations of their tumours
PMID: 33303901 Journal: BONE MARROW TRANSPLANTATION Year: 2021 Reference: Bone Marrow Transplant. 2021 May;56(5):1213-1216. doi: 10.1038/s41409-020-01172-y. Epub 2020 Dec 10. Impact factor: 5.483 Publication type: Paper in international publication Authors: Murillo-Sanjuan, L, Gonzalez-Vicent, M, Argiles Aparicio, B, Badell Serra, I, Rodriguez Villa, A, Uria Oficialdegui, M L, Lopez-Duarte, M, Belendez-Bieler, C, Sastre Urgelles, A, Sevilla Navarro, J et al. DOI: 10.1038/s41409-020-01172-y
PMID: 33827367 Journal: LEUKEMIA & LYMPHOMA Year: 2021 Reference: Leuk Lymphoma. 2021 Sep;62(9):2202-2210. doi: 10.1080/10428194.2021.1907375. Epub 2021 Apr 7. Impact factor: 3.28 Publication type: Review in international publication Authors: Hidalgo-Gomez, Gloria, Palacio-Garcia, Carlos, Gallur, Laura, Blanco, Adoracion, Tazon-Vega, Barbara, Saumell, Silvia, Martinez, Noemi, Murillo, Laura, Murciano, Thais, Velasco, Pablo et al. DOI: 10.1080/10428194.2021.1907375
PMID: 33781716 Journal: ANALES DE PEDIATRIA Year: 2021 Reference: An Pediatr (Engl Ed). 2021 Mar 26. pii: S1695-4033(21)00148-X. doi: 10.1016/j.anpedi.2021.02.015. Impact factor: 1.5 Publication type: Paper in national publication Authors: Galan Gomez, Victor, de la Fuente Regano, Lydia, Rodriguez Villa, Antonia, Diaz de Heredia Rubio, Cristina, Gonzalez Vicent, Marta, Badell Serra, Isabel, Fernandez, Jose Maria, Pascual Martinez, Antonia Isabel, Perez Hurtado, Jose Maria, Lopez Duarte, Monica et al. DOI: 10.1016/j.anpedi.2021.02.015
PMID: 32979154 Journal: INFECTION Year: 2021 Reference: Infection. 2021 Apr;49(2):215-231. doi: 10.1007/s15010-020-01521-5. Epub 2020 Sep 26. Impact factor: 3.553 Publication type: Review in international publication Authors: Los-Arcos, Ibai, Alsina-Manrique, Laia, Diaz de Heredia, Cristina, Fortuny-Guasch, Claudia, Garcia-Cadenas, Irene, Garcia-Vidal, Carolina, Gonzalez-Vicent, Marta, Hernani, Rafael, Kwon, Mi, Machado, Marina et al. DOI: 10.1007/s15010-020-01521-5
PMID: 32203264 Journal: BONE MARROW TRANSPLANTATION Year: 2020 Reference: Bone Marrow Transplant. 2020 Sep;55(9):1796-1809. doi: 10.1038/s41409-020-0863-z. Epub 2020 Mar 19. Impact factor: 4.725 Publication type: Review in international publication Authors: Pochon, Cecile, Menconi, Maria Cristina, Bosman, Paul, Mauro, Margherita, Tridello, Gloria, de Latour, Regis Peffault, Dufour, Carlo, Afanasyev, Boris, Stein, Jerry, Krivan, Gergely et al. DOI: 10.1038/s41409-020-0863-z
PMID: 32179448 Journal: EUROPEAN JOURNAL OF CANCER Year: 2020 Reference: Eur J Cancer. 2020 May;130:72-80. doi: 10.1016/j.ejca.2020.01.029. Epub 2020 Mar 13. Impact factor: 7.275 Publication type: Paper in international publication Authors: Ferrari, Andrea, Merks, Johannes H M, Chisholm, Julia C, Orbach, Daniel, Brennan, Bernadette, Gallego, Soledad, van Noesel, Max M, McHugh, Kieran, van Rijn, Rick R, Gaze, Mark N et al. DOI: 10.1016/j.ejca.2020.01.029
PMID: 32133691 Journal: TRANSPLANT INTERNATIONAL Year: 2020 Reference: Transpl Int. 2020 Jul;33(7):762-772. doi: 10.1111/tri.13601. Epub 2020 Apr 2. Impact factor: 3.177 Publication type: Paper in international publication Authors: Lawitschka, A, Dalle, J-H, Balduzzi, A, Gibson, B, Diaz De Heredia, C, Wachowiak, J, Dalissier, A, Vettenranta, K, Yaniv, I, Bordon, V et al. DOI: 10.1111/tri.13601
PMID: 32142919 Journal: CANCER LETTERS Year: 2020 Reference: Cancer Lett. 2020 May 1;477:49-59. doi: 10.1016/j.canlet.2020.02.035. Epub 2020 Mar 3. Impact factor: 7.36 Publication type: Paper in international publication Authors: Molist, C, Navarro, N, Giralt, I, Zarzosa, P, Gallo-Oller, G, Pons, G, Magdaleno, A, Moreno, L, Guillen, G, Hladun, R et al. DOI: 10.1016/j.canlet.2020.02.035
The association, once again, has shown its commitment to oncological research with a donation of €19,197 to the Cancer and Hematological Diseases Group for Children at VHIR.
The prestigious journal The Lancet has published the results of this study, which is the result of more than 20 years of pre-clinical research and 7 years of patient follow-up.
During the meeting, the role of the Vall d'Hebron Paediatric Research Hub in promoting research on children and adolescents was highlighted.
